



**TO**  
All Providers, HMOs and Other Managed Care Programs

**REGARDING**  
New Procedure Codes for Remdesivir COVID-19 Treatment and COVID-19 Monoclonal Antibodies

**New Procedure Codes for Remdesivir COVID-19 Treatment and COVID-19 Monoclonal Antibodies**

ForwardHealth will accept and process claims for the following new procedure codes effective on and after the dates of service associated with each procedure code in the table below.

PROCEDURE CODE	DESCRIPTION	EFFECTIVE DATE
J0248	Injection, remdesivir, 1 mg	December 23, 2021
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring	December 8, 2021

PROCEDURE CODE	DESCRIPTION	EFFECTIVE DATE
M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	December 8, 2021
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg	December 8, 2021

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources page](#) of the ForwardHealth Portal.